论文信息 - A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC). - 字舞流文

A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC).

W. Linehan | R. Srinivasan | T. Choueiri | U. Vaishampayan | S. Shankar | Theodore F. Logan | Laurie Sherman | Yuan Liu